GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Cyclically Adjusted PS Ratio

Medexus Pharmaceuticals (TSX:MDP) Cyclically Adjusted PS Ratio : 0.45 (As of Apr. 28, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-04-28), Medexus Pharmaceuticals's current share price is C$1.92. Medexus Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was C$4.24. Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 0.45.

The historical rank and industry rank for Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

TSX:MDP' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.26   Med: 0.53   Max: 1.02
Current: 0.45

During the past years, Medexus Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 1.02. The lowest was 0.26. And the median was 0.53.

TSX:MDP's Cyclically Adjusted PS Ratio is ranked better than
88.86% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs TSX:MDP: 0.45

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Medexus Pharmaceuticals's adjusted revenue per share data for the three months ended in Dec. 2023 was C$1.399. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is C$4.24 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Medexus Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Medexus Pharmaceuticals Annual Data
Trend Dec13 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.92 0.41

Medexus Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.41 0.46 0.73 0.58

Competitive Comparison of Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Medexus Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.92/4.24
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Medexus Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.399/125.4675*125.4675
=1.399

Current CPI (Dec. 2023) = 125.4675.

Medexus Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.895 96.945 1.158
201406 0.187 99.473 0.236
201409 0.191 99.394 0.241
201412 0.175 98.367 0.223
201503 0.033 99.789 0.041
201506 0.125 100.500 0.156
201509 0.301 100.421 0.376
201512 0.209 99.947 0.262
201603 0.179 101.054 0.222
201606 0.184 102.002 0.226
201609 0.388 101.765 0.478
201612 0.363 101.449 0.449
201703 0.351 102.634 0.429
201706 0.480 103.029 0.585
201709 0.524 103.345 0.636
201712 0.411 103.345 0.499
201803 0.325 105.004 0.388
201806 0.556 105.557 0.661
201809 0.597 105.636 0.709
201812 1.070 105.399 1.274
201903 0.899 106.979 1.054
201906 1.107 107.690 1.290
201909 0.997 107.611 1.162
201912 1.153 107.769 1.342
202003 1.818 107.927 2.113
202006 1.875 108.401 2.170
202009 1.626 108.164 1.886
202012 2.149 108.559 2.484
202103 1.273 110.298 1.448
202106 1.101 111.720 1.236
202109 1.163 112.905 1.292
202112 1.380 113.774 1.522
202203 1.300 117.646 1.386
202206 1.479 120.806 1.536
202209 1.849 120.648 1.923
202212 1.948 120.964 2.021
202303 1.770 122.702 1.810
202306 2.072 124.203 2.093
202309 2.008 125.230 2.012
202312 1.399 125.468 1.399

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Medexus Pharmaceuticals  (TSX:MDP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Medexus Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medexus Pharmaceuticals (TSX:MDP) Business Description

Traded in Other Exchanges
Address
35 Nixon Road, Suite 1, Bolton, ON, CAN, L7E 1K1
Medexus Pharmaceuticals Inc is an innovative and rare disease pharmaceutical company with a strong North American commercial platform and a portfolio of proven best-in-class products. The company's focus is on the therapeutic areas of hematology, auto-immune diseases, and allergy.